US FDA panel backs approval for Eisai-Biogen Alzheimer’s drug Leqembi, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

Leqembi won accelerated approval by the FDA in January based on its ability to remove sticky amyloid plaques from the brain. The panel on Friday considered Eisai’s large confirmatory trial designed to show the drug benefited patients., Leqembi won accelerated approval by the FDA in January based on its ability to remove sticky amyloid plaques from the brain. The panel on Friday considered Eisai’s large confirmatory trial designed to show the drug benefited patients., , Read More

Leave a Reply

Your email address will not be published.